Evidence map›Paper›PMID 41122645›Full record

ArticleFrontiers in oncology2025

CORO1A: a pan-cancer prognosis, diagnostic and immune biomarker based on breast cancer validation.

Dilraba Elihamu, Yongxiang Li, Yiyang Wang, Haiyan Cui, Yiting Xing, Haohao Peng, Dilimulati Ismtula, Chenming Guo

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Intratumoral PD-1Medical oncology (Northwood, London, England) · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dilraba Elihamu *Department of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yongxiang Li *Department of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yiyang Wang *Department of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Haiyan CuiThyroid and Breast Surgery Department of the People's Hospital of Bayingolin Mongol Autonomous Prefecture, Korla, China.
Yiting XingDepartment of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Haohao PengDepartment of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Dilimulati IsmtulaDepartment of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Chenming GuoDepartment of Breast Surgery, Center of Digestive and Vascular Surgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: CORO1A, a constituent of the Coronins family, is a conserved protein throughout evolution that interacts with actin within the cellular environment besides being involved in various malignancy development. Methods: A comprehensive analysis examining the discrepancies in expression levels, survival outcomes, immune cell infiltration (ICI), and enrichment profiles was performed. The expression of CORO1A in breast cancer tissues was verified by immunohistochemistry, WB and RT-qPCR experiments. The effects of different expression levels of CORO1A on the growth and metastasis of breast cancer cell lines were verified by CCK-8, colony formation, Trasnwell and cell scratch experiments. Results: The findings revealed a heightened expression of CORO1A in the 66.7% of tumor types (22/33), CORO1A consistently demonstrates high diagnostic potential and variable prognostic significance across cancers. In particular, its diagnostic value in SKCM reaches as high as 98%, with a prognostic hazard ratio of 0.77. CORO1A often characterized by hypomethylation of its promoter region, which correlates with the ICI level. Enrichment analysis highlights the critical contribution of CORO1A in B cell receptor pathways and other immune-linked processes, CORO1A may have multiple potential roles in B-cell receptor pathways, involving aspects such as signal transduction regulation, cytoskeletal remodeling and migration, as well as interactions with other immune molecules. exerting a substantial influence on patient prognosis. CORO1A is highly expressed in breast cancer tissues. Breast cancer patients with high expression of CORO1A have a good prognosis. CORO1A knockdown inhibits the growth and metastasis of breast cancer cells, while overexpression is the opposite. Therefore, due to its high diagnostic sensitivity and prognostic value demonstrated in various cancers, CORO1A holds promise as a candidate molecule for novel targeted therapies. Discussion: CORO1A, as a promising research target, has demonstrated significant and specific capabilities in predicting disease prognosis, analyzing immune responses, and exploring therapeutic approaches for different types of tumors, further highlighting the necessity for in-depth research on it.

Indexed as

breast cancerCORO1Apan-cancerprognosistumor immunity

Identifiers

PMID41122645
PMCPMC12535887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.